Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 1999 March;47(3) > Minerva Cardioangiologica 1999 March;47(3):55-8



A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Frequency: Bi-Monthly

ISSN 0026-4725

Online ISSN 1827-1618


Minerva Cardioangiologica 1999 March;47(3):55-8


Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy

Trifiletti A., Bartolone S., Scamardi R., Pizzoleo M. A., Attinà A., Sottilotta G., Canobbio V., Soraci S., Barbera N.

Background. In this study the action of a prostaglandin, PGE1, was studied in a group of patients with peripheral arterial occlusive disease (PAOD).
Methods. In 16 patients (14 men and 2 women, aged 47-70 years, mean 57±7) with PAOD, Fontaine stage IIb and III in critical ischemia, the effects on two indexes of thrombin generation and action of the endovenous administration (2 hours) of 60 mg of Alprostadil-PGE1 for four weeks were evaluated. In all artheriopathic patients, before and after pharmacological treatment, the following haemostatic parameters were evaluated: the prothrombin fragment 1+2 (F1+2) and the fibrinopeptide A(FPA).
Results. The patients showed plasma levels of FPA significantly decreased at the end of the treatment. On the other hand, no significant difference in plasma F1+2 levels was observed after treatment.
Conclusions. These results seem to indicate that plasma F1+2 levels are significantly elevated, as a marker of thrombosis status, in patients with PAOD before and after treatment with PGE1.

language: English, Italian


top of page